Clinical trial
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0973/XL518 Administered Orally Daily to Subjects With Solid Tumors
NCT00467779 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0973/XL518 Administered Orally Daily to Subjects With Solid Tumors
- Lead sponsor
- Genentech, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 31, 2007
- Completion date
- April 30, 2014
- Enrollment
- 119 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
solid tumor